2018
DOI: 10.7150/ijms.28055
|View full text |Cite
|
Sign up to set email alerts
|

NDRG1 Downregulates ATF3 and Inhibits Cisplatin-Induced Cytotoxicity in Lung Cancer A549 Cells

Abstract: N-myc downstream regulated gene 1 (NDRG1) plays a variety of roles in human cancers. Our previous studies showed that NDRG1 expression is elevated in non-small cell lung cancer and contributes to cancer growth. However, its function in apoptosis and chemoresistance in malignant tumors, including lung cancer, is not yet fully understood. In this study, we investigated the roles of NDRG1 in chemoresistance to cisplatin in lung cancer cells. We found that overexpression of NDRG1 significantly reduced cisplatin-in… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
13
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 18 publications
(14 citation statements)
references
References 21 publications
1
13
0
Order By: Relevance
“…Cisplatin (CP) is a chemotherapeutic drug that has been used clinically for decades in patients with malignant tumors; however, nephrotoxicity, which is the major side effect of CP treatment, has greatly limited its application as a treatment ( 1 , 2 ). Thus, there is an urgent requirement to develop a novel therapeutic agent that protects against CP-induced renal injury and obtain novel insights into the treatment of patients with cancer undergoing CP-based chemotherapy regimens ( 3 , 4 ).…”
Section: Introductionmentioning
confidence: 99%
“…Cisplatin (CP) is a chemotherapeutic drug that has been used clinically for decades in patients with malignant tumors; however, nephrotoxicity, which is the major side effect of CP treatment, has greatly limited its application as a treatment ( 1 , 2 ). Thus, there is an urgent requirement to develop a novel therapeutic agent that protects against CP-induced renal injury and obtain novel insights into the treatment of patients with cancer undergoing CP-based chemotherapy regimens ( 3 , 4 ).…”
Section: Introductionmentioning
confidence: 99%
“…Although chemotherapy is the main treatment method, its side-effects pose a significant challenge. Therefore, alternative chemotherapeutic drugs and those that reduce the side-effects of chemotherapy are required ( 34 ). Studies have demonstrated that sphingolipid metabolism-targeted therapy may have broad prospects in oncological clinical application.…”
Section: Discussionmentioning
confidence: 99%
“…We found in A549 and IMR90 cells that cisplatin and phenanthriplatin both upregulated ATF3 (activating transcription factor 3) more than any other gene ( Table 1 , Table 2 and Table 3 ). Overexpression of ATF3 is associated with apoptosis and promotes cytotoxicity in cisplatin treated A549 cells via p53 signaling [ 23 ]. Furthermore, expression of N-myc downstream regulated gene 1 (NDRG1), a gene that is regulated by hypoxia and cellular proliferation signaling, and can act to both promote and suppress some cancers, has been shown to counteract the function of ATF3 [ 23 ].…”
Section: Discussionmentioning
confidence: 99%
“…Overexpression of ATF3 is associated with apoptosis and promotes cytotoxicity in cisplatin treated A549 cells via p53 signaling [ 23 ]. Furthermore, expression of N-myc downstream regulated gene 1 (NDRG1), a gene that is regulated by hypoxia and cellular proliferation signaling, and can act to both promote and suppress some cancers, has been shown to counteract the function of ATF3 [ 23 ]. These results suggest that both cisplatin and the monofunctional complex can potentially suppress NDRG1’s action to suppress ATF3.…”
Section: Discussionmentioning
confidence: 99%